109 related articles for article (PubMed ID: 10353617)
1. In vivo amifostine (WR-2721) prevents chemotherapy-induced apoptosis of peripheral blood lymphocytes from cancer patients.
Provinciali M; Ciavattini A; Di Stefano G; Argentati K; Garzetti GG
Life Sci; 1999; 64(17):1525-32. PubMed ID: 10353617
[TBL] [Abstract][Full Text] [Related]
2. Amifostine modulates radio-induced apoptosis of peripheral blood lymphocytes in head and neck cancer patients.
Saavedra MM; Henríquez-Hernández LA; Lara PC; Pinar B; Rodríguez-Gallego C; Lloret M
J Radiat Res; 2010; 51(5):603-7. PubMed ID: 20699603
[TBL] [Abstract][Full Text] [Related]
3. The potential of amifostine: from cytoprotectant to therapeutic agent.
Santini V; Giles FJ
Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
[TBL] [Abstract][Full Text] [Related]
4. Flow cytometric detection of apoptotic bone marrow cells with fractional DNA content after application of WR-2721, cyclophosphamide, cisplatin, and exposure of mice to gamma rays.
Mazur L; Czyzewska A; Bochenek M
Hum Exp Toxicol; 2002 Jun; 21(6):335-41. PubMed ID: 12195937
[TBL] [Abstract][Full Text] [Related]
5. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy.
Capizzi RL; Scheffler BJ; Schein PS
Cancer; 1993 Dec; 72(11 Suppl):3495-501. PubMed ID: 8242582
[TBL] [Abstract][Full Text] [Related]
6. Amifostine can differentially modulate DNA double-strand breaks and apoptosis induced by idarubicin in normal and cancer cells.
Wozniak K; Gloc E; Morawiec Z; Blasiak J
Exp Oncol; 2008 Mar; 30(1):22-8. PubMed ID: 18438337
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin-based polychemotherapy reduces the natural cytotoxicity of peripheral blood mononuclear cells in patients with advanced ovarian carcinoma and their in vitro responsiveness to interleukin-12 incubation.
Garzetti GG; Ciavattini A; Muzzioli M; Romanini C
Cancer; 1999 May; 85(10):2226-31. PubMed ID: 10326702
[TBL] [Abstract][Full Text] [Related]
8. Radioprotective effects of amifostine in vitro and in vivo measured with the comet assay.
Müller AC; Pigorsch S; Beyer C; Lautenschläger C; Dunst J
Strahlenther Onkol; 2004 Aug; 180(8):517-25. PubMed ID: 15292973
[TBL] [Abstract][Full Text] [Related]
9. Effects of WR-2721 and cyclophosphamide on the cell cycle phase specificity of apoptosis in mouse bone marrow.
Mazur L; Augustynek A; Deptała A; Halicka HD; Bedner E
Anticancer Drugs; 2002 Aug; 13(7):751-8. PubMed ID: 12187332
[TBL] [Abstract][Full Text] [Related]
10. Amifostine for protection from antineoplastic drug toxicity.
Foster-Nora JA; Siden R
Am J Health Syst Pharm; 1997 Apr; 54(7):787-800. PubMed ID: 9099346
[TBL] [Abstract][Full Text] [Related]
11. Immunocytochemical analysis of apoptotic bone marrow cells after treatment of mice with WR-2721 and chemotherapeutic drugs.
Mazur L; Czyzewska A
Folia Histochem Cytobiol; 2001; 39(2):63-6. PubMed ID: 11374841
[TBL] [Abstract][Full Text] [Related]
12. Effects of amifostine (WR-2721, ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas.
Fichtner I; Lemm M; Becker M; Berthold F
Anticancer Drugs; 1997 Feb; 8(2):174-81. PubMed ID: 9073313
[TBL] [Abstract][Full Text] [Related]
13. Differential antigenotoxic and cytoprotective effect of amifostine in idarubicin-treated mice.
de Campos Nebel M; Larripa I; González-Cid M
Environ Mol Mutagen; 2002; 39(1):3-9. PubMed ID: 11813290
[TBL] [Abstract][Full Text] [Related]
14. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
[TBL] [Abstract][Full Text] [Related]
15. A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).
Gradishar WJ; Stephenson P; Glover DJ; Neuberg DS; Moore MR; Windschitl HE; Piel I; Abeloff MD
Cancer; 2001 Nov; 92(10):2517-22. PubMed ID: 11745184
[TBL] [Abstract][Full Text] [Related]
16. Modulatory effect of amifostine (WR-1065) against genotoxicity and oxidative stress induced by methotrexate in human umbilical vein endothelial cells (HUVECs).
Aghajanshakeri S; Salmanmahiny A; Aghajanshakeri S; Babaei A; Alishahi F; Babayani E; Shokrzadeh M
Toxicol Mech Methods; 2023 Nov; 33(9):755-765. PubMed ID: 37537746
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of WR-151327: an orally active chemotherapy protector.
Green D; Bensely D; Schein P
Cancer Res; 1994 Feb; 54(3):738-41. PubMed ID: 8306335
[TBL] [Abstract][Full Text] [Related]
18. A potential synergistic anticancer effect of paclitaxel and amifostine on endometrial cancer.
Dai D; Holmes AM; Nguyen T; Davies S; Theele DP; Verschraegen C; Leslie KK
Cancer Res; 2005 Oct; 65(20):9517-24. PubMed ID: 16230417
[TBL] [Abstract][Full Text] [Related]
19. Amifostine enhances recovery and expansion of peripheral FAS/CD95+ T- and NK-cell subpopulations during radiotherapy of patients with head-neck cancer.
Koukourakis GV; Baksevanis CN; Zambatis H; Gritzapis A; Maltezos E; Simopoulos C; Koukourakis MI
Int J Radiat Biol; 2009 Jan; 85(1):96-104. PubMed ID: 19205988
[TBL] [Abstract][Full Text] [Related]
20. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
Kurbacher CM; Mallmann PK
Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
